EDOC News and Press, Global X Telemedicine & Digital Health ETF From 07/01/22

Teladoc is officially a value stock, trading at a price-to-book discount. Impairment losses dealt a big blow to investors. However, operating performance can't be doubted. The company is growing its market share in the telehealth space by acquiring hypergrowth companies that provi...

Teladoc is down 90% from its ATH and I sold my position at a 75% loss. In this article, I will discuss what went wrong. I missed a lot of red flags about Teladoc, like low insider ownership and bad capital allocation. I ignored several of my investing rules and wasn't objective. ...

The first five months of the year marked the worst start for the S&P 500 since 1970 ― and the sixth worst back to 1928. Stock valuations have come down, but company earnings remain solid. Earnings will slow, but 20% is hard to imagine, even in a recession. For fur...

Today, we profile Personalis, a small cancer genomics testing firm. The stock has taken a battering in 2022 and is posting substantial quarterly losses, but shares now sell for less than net cash. 2022 is a transition year for the company in many ways. An investment analysis ...

Despite these turbulent global markets, we can identify several clear positives across the thematic space. As a result, we believe that it may be a good time for investors to seek exposure to these themes at the dip while keeping their focus on the long-term drivers. As this econo...

How similar will the next three or five years look from the years that immediately preceded the pandemic? And what are the implications for us as global equity investors? We don’t expect anything like the hyperinflation and stagflation we experienced in the 1970s; our outlook s...

With the world facing inflationary and geopolitical hurdles, economic growth is poised to slow. Shares across sectors have been hit hard. Investors in growth stocks must identify companies with the right features to overcome headwinds to earnings. For further details see: ...

Healthcare, Staples, and Utilities continue to outperform as selling intensifies in the growth style. Investor positioning is still light in the space – even after a year of alpha. While absolute valuations have turned somewhat pricey, the defensive supersector shows decent...

During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...

TDOC investors were burned when the company reported $6.67B of net losses for FQ1'22. It is evident that TDOC finally admitted to their Livongo folly, though it is the investors who are feeling the pain. Nonetheless, if we were to omit the $6.6B impairment cost, the company's fina...